News

Rising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Target

Research targeting the insulin-inhibitory receptor, called inceptor, unveils promising avenues for beta cell protection, offering hope for causal diabetes therapy. A novel study in mice with diet-induced obesity demonstrates that the knock-out of inceptor enhances glucose regulation, prompting its further exploration as a drug target for type 2 diabetes treatment.

Insulin-producing beta cells in the islet of Langerhans. Helmholtz Munich | ©Erik Bader


These findings, led by Helmholtz Munich in collaboration with the German Center for Diabetes Research, the Technical University of Munich, and the Ludwig-Maximilians-University Munich, drive advancements in diabetes research.

Further information on these research results, that have been published in Nature Metabolism, can be found in the press release of our DZD partner Helmholtz Munich.